GlassScriptPhysician profile
Sonia M Canaves Nunez
NPI 1437184843
$11,009.58
in general payments reported to CMS, 2019-2025
57 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $1,025 · 2021: $1,224 · 2022: $1,167 · 2023: $1,516 · 2024: $2,373 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.72 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $970.51 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $770.25 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Genzyme Corporation | $638.28 | 2019-2023 | |
| Biogen, INC. | $584.64 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $543.55 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $529.61 | 2019-2024 | Nayzilam |
| Collegium Pharmaceutical, INC. | $436.71 | 2019-2024 | Xtampza |
| Allergan, INC. | $384.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $376.12 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.70 | 2021-2025 | Relistor |
| Amneal Pharmaceuticals LLC | $361.23 | 2021-2025 | Crexont, Ongentys, Ongentys 50mg Capsules 30 |
| Emd Serono, INC. | $342.72 | 2019-2025 | |
| Eisai INC. | $304.52 | 2020-2025 | |
| Lilly USA, LLC | $245.53 | 2019-2025 | Amyvid, Kisunla, Emgality |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Canaves Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.